Get the Stockscreener App
317.09
0.93%
2.92
Pre-market:
317.50
0.41
+0.13%
Madrigal Pharmaceuticals Inc stock is traded at $317.09, with a volume of 271.69K.
It is up +0.93% in the last 24 hours and up +47.87% over the past month.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
See More
Previous Close:
$314.17
Open:
$315.75
24h Volume:
271.69K
Relative Volume:
0.74
Market Cap:
$6.92B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-16.48
EPS:
-19.24
Net Cash Flow:
$-438.32M
1W Performance:
+0.62%
1M Performance:
+47.87%
6M Performance:
+36.62%
1Y Performance:
+66.85%
1-Day Range:
$310.83
$323.99
1-Week Range:
$272.72
$323.99
52-Week Range:
$168.25
$368.29
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MDGL | 317.09 | 6.92B | 0 | -518.67M | -438.32M | -19.24 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Connor Clark & Lunn Investment Management Ltd. Sells 10,979 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra (MDGL:NASDAQ) - Seeking Alpha
Madrigal Pharmaceuticals Engages with Investors at Key Conferences - MSN
Madrigal Pharmaceuticals (NASDAQ:MDGL) Given "Neutral" Rating at Cantor Fitzgerald - MarketBeat
Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH - Scrip
(11/18/24) MDGL: A Promising Play in the Weight Loss Drug Space - Moneyshow.com
Madrigal Pharmaceuticals gains amid takeover speculation - MSN
John Paulson's Strategic Acquisition in Madrigal Pharmaceuticals - GuruFocus.com
Janus Henderson Group PLC's Strategic Reduction in Madrigal Phar - GuruFocus.com
RTW INVESTMENTS, LP Expands Stake in Madrigal Pharmaceuticals Inc - GuruFocus.com
(MDGL) Trading Report - Stock Traders Daily
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More - AOL
Fiera Capital Corp Sells 3,535 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Madrigal Pharmaceuticals director Richard Levy sells $1.75 million in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals director Richard Levy sells $1.75 million in stock - Investing.com India
3 High Growth Tech Stocks Leading The US Market - Simply Wall St
B. Riley Has Bullish Estimate for MDGL FY2024 Earnings - MarketBeat
Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy - Yahoo Finance
Madrigal Pharmaceuticals (FRA:YDO1) Current Ratio : 5.98 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences - The Manila Times
Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan
Analysts Offer Predictions for MDGL Q1 Earnings - MarketBeat
Madrigal Pharmaceuticals director Richard Levy sells $1.5m in shares - Investing.com
Madrigal Pharmaceuticals director Richard Levy sells $1.5m in shares By Investing.com - Investing.com UK
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart
B. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
MDGL (Madrigal Pharmaceuticals) Change In Receivables : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Check Out What Whales Are Doing With MDGL - Benzinga
Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectat - GuruFocus.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 1-Year High After Analyst Upgrade - MarketBeat
Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations - Yahoo Finance
FY2028 Earnings Forecast for MDGL Issued By Leerink Partnrs - MarketBeat
Emerald Advisers LLC Has $5.79 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? - Benzinga
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion - Seeking Alpha
(MDGL) Long Term Investment Analysis - Stock Traders Daily
Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance
Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - Simply Wall St
Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts - Yahoo Finance
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up - MSN
Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances - MSN
MDGL stock soars to 52-week high, reaching $299.99 By Investing.com - Investing.com South Africa
Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat - MSN
Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets. - Investor's Business Daily
Madrigal Pharmaceuticals stock jumps on MASH drug hopes - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $441.00 - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Releases Earnings Results, Beats Expectations By $2.02 EPS - MarketBeat
MDGL stock soars to 52-week high, reaching $299.99 - Investing.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Sees Strong Trading Volume Following Earnings Beat - MarketBeat
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):